Vidac Pharma has attracted attention at the First Pediatric Brain Tumor Research Meeting in Jerusalem. Dr. Max Herzberg, CEO of the Company, presented data on the drug candidate VDA-1102, which successfully penetrated the blood-brain barrier in a 5-year-old patient as part of a special program. "This is a significant milestone that opens up new possibilities for breakthrough therapies in brain diseases," emphasized Herzberg. The ability to achieve therapeutic concentrations in the tumor could revolutionize the treatment of aggressive brain diseases, not only in children.
News & Events